U.S. Food and Drug Administration (FDA) Accepts Teva's New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

Core Viewpoint - Teva Pharmaceuticals and Medincell announced that the FDA has accepted the New Drug Application for TEV-'749, an extended-release injectable suspension of olanzapine aimed at improving treatment adherence for schizophrenia patients [1][2][3] Company Overview - Teva Pharmaceutical Industries Ltd. is transitioning into a leading innovative biopharmaceutical company, supported by a strong generics business, with a focus on neuroscience and immunology [8] - Medincell is a biopharmaceutical company developing long-acting injectable drugs, utilizing proprietary technology to enhance medication compliance and effectiveness [10] Product Details - TEV-'749 is a once-monthly subcutaneous injection of olanzapine, designed to address the lack of long-acting formulations without the need for post-injection monitoring [2][6] - The product utilizes SteadyTeq™, a proprietary copolymer technology from Medincell, which allows for controlled and sustained release of olanzapine [4] Clinical Trial Insights - The NDA for TEV-'749 is based on the Phase 3 SOLARIS trial, which demonstrated an efficacy and safety profile consistent with existing olanzapine formulations [3][5] - The SOLARIS trial involved 675 patients aged 18 to 64, randomized to receive TEV-'749 or placebo, with a primary objective to evaluate efficacy in treating schizophrenia [5] Market Need - There is a significant unmet need for long-acting olanzapine formulations, as treatment adherence remains a major challenge for schizophrenia patients [3][6] - Approximately 1% of the global population will develop schizophrenia, with 3.5 million diagnosed in the U.S., highlighting the potential market for TEV-'749 if approved [7]